Known hypersensitivity to benralizumab or excipients.
WARNINGS AND Safeguards
Acute Bronchial asthma Signs and symptoms or Failing Disease
FASENRA shouldn’t be accustomed to treat acute bronchial asthma signs and symptoms, acute exacerbations, or acute bronchospasm.
FASENRA may be the only respiratory system biologic that gives direct, rapid and near-complete depletion of eosinophils within 24 hrs, as noticed in a Phase II study. Eosinophils are a kind of white-colored bloodstream cell which are an ordinary area of the body’s defense mechanisms. Elevated amounts of eosinophils, observed in about 50 % of severe bronchial asthma patients, impact airway inflammation and airway hyper-responsiveness, leading to elevated bronchial asthma severity and signs and symptoms, decreased breathing and elevated chance of exacerbations.
The most typical side effects (incidence ≥ 5%) include headache and pharyngitis.